JP2021502323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502323A5 JP2021502323A5 JP2019535295A JP2019535295A JP2021502323A5 JP 2021502323 A5 JP2021502323 A5 JP 2021502323A5 JP 2019535295 A JP2019535295 A JP 2019535295A JP 2019535295 A JP2019535295 A JP 2019535295A JP 2021502323 A5 JP2021502323 A5 JP 2021502323A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- disulfandylbis
- acetamide
- propanamide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229910052805 deuterium Inorganic materials 0.000 claims 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- DVOVBGJJSFSOPZ-UHFFFAOYSA-N 2-acetamidopropanamide Chemical compound NC(=O)C(C)NC(C)=O DVOVBGJJSFSOPZ-UHFFFAOYSA-N 0.000 claims 5
- YVDBIXASASLJPM-BYPYZUCNSA-N (2r)-n-acetyl-2-amino-3-sulfanylpropanamide Chemical class CC(=O)NC(=O)[C@@H](N)CS YVDBIXASASLJPM-BYPYZUCNSA-N 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- PNROREDTZJCOHF-UHFFFAOYSA-N 2-(3,5-dichlorophenoxy)acetonitrile Chemical compound ClC1=CC(Cl)=CC(OCC#N)=C1 PNROREDTZJCOHF-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000034656 Contusions Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 230000001147 anti-toxic effect Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000009519 contusion Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000012268 mitochondrial disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000004792 oxidative damage Effects 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 claims 1
- SUSMHLGLLFPYER-UHFFFAOYSA-N acetamide;propanamide Chemical compound CC(N)=O.CCC(N)=O SUSMHLGLLFPYER-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 0 *C(N[C@@](CS)C(N)=O)=O Chemical compound *C(N[C@@](CS)C(N)=O)=O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583984P | 2017-11-09 | 2017-11-09 | |
| US62/583,984 | 2017-11-09 | ||
| US201762587246P | 2017-11-16 | 2017-11-16 | |
| US62/587,246 | 2017-11-16 | ||
| US16/180,984 | 2018-11-05 | ||
| US16/180,984 US20190135741A1 (en) | 2017-11-09 | 2018-11-05 | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| PCT/US2018/059446 WO2019094383A1 (en) | 2017-11-09 | 2018-11-06 | Methods of making deuterium-enriched n-acetylcysteine amide (d-naca) and (2r,2r')-3,3' -disulfanediyl bis(2-acetamidopropanamide) (dinaca) and using d-naca and dinaca to treat diseases involving oxidative stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502323A JP2021502323A (ja) | 2021-01-28 |
| JP2021502323A5 true JP2021502323A5 (https=) | 2021-12-02 |
Family
ID=66328243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535295A Pending JP2021502323A (ja) | 2017-11-09 | 2018-11-06 | 重水素濃縮ｎ−アセチルシステインアミド（ｄ−ｎａｃａ，ｄｅｕｔｅｒｉｕｍ−ｅｎｒｉｃｈｅｄ ｎ−ａｃｅｔｙｌｃｙｓｔｅｉｎｅ ａｍｉｄｅ）及び（２ｒ，２ｒ’）−３，３’−ジスルファンジイルビス（２−アセトアミドプロパンアミド）（ｄｉｎａｃａ）を作製する、並びに酸化ストレスが関与する疾患を治療するためにｄ−ｎａｃａ及びｄｉｎａｃａを使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190135741A1 (https=) |
| EP (1) | EP3534890A4 (https=) |
| JP (1) | JP2021502323A (https=) |
| KR (2) | KR20220016304A (https=) |
| CN (1) | CN111201017A (https=) |
| AU (4) | AU2018365900B2 (https=) |
| CA (2) | CA3131442A1 (https=) |
| RU (1) | RU2019126848A (https=) |
| WO (1) | WO2019094383A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| US11091433B2 (en) * | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20230159448A1 (en) * | 2017-09-20 | 2023-05-25 | Nacuity Pharmaceuticals, Inc. | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP4054553A4 (en) * | 2019-11-08 | 2023-11-29 | Retina Foundation of the Southwest | JOINTS AND IMPLANTS FOR THE TREATMENT OF EYE DISEASES |
| WO2021146556A1 (en) * | 2020-01-16 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Real-time monitoring of in vivo free radical scavengers through hyperpolarized n-acetyl cysteine isotopes |
| AU2021209953B2 (en) * | 2020-01-24 | 2024-08-22 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
| US20210378993A1 (en) * | 2020-06-08 | 2021-12-09 | Nacuity Pharmaceuticals, Inc. | Treatment of cystinosis |
| US11883426B2 (en) * | 2020-08-08 | 2024-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatment for methamphetamine cardiovascular disease |
| US20220304955A1 (en) * | 2021-03-23 | 2022-09-29 | Nacuity Pharmaceuticals, Inc. | Treatment of ferroptosis |
| CA3242202A1 (en) | 2022-01-26 | 2023-08-03 | Universidade De Aveiro | IONIC LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES |
| WO2026015776A1 (en) * | 2024-07-12 | 2026-01-15 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3252866A (en) | 1965-06-28 | 1966-05-24 | Mead Johnson & Co | 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US20030027745A1 (en) | 2001-06-13 | 2003-02-06 | Repine John E. | Diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| US20060211628A1 (en) | 2002-08-02 | 2006-09-21 | Daphne Atlas | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| AU2013299785B2 (en) | 2012-08-06 | 2017-09-07 | Baylor College Of Medicine | Therapeutics dispensing device and methods of making same |
| EP2928562A4 (en) | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| US9763902B2 (en) | 2014-03-28 | 2017-09-19 | Nacuity Pharmaceuticals, Inc | Method for preparation of N-acetyl cysteine amide |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| JP7418958B2 (ja) * | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
| JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミン感受性障害の治療方法 |
| EP3684756A4 (en) * | 2017-09-20 | 2020-10-28 | NaCuity Pharmaceuticals, Inc. | SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES |
| WO2019060704A1 (en) | 2017-09-22 | 2019-03-28 | University Of Florida Research Foundation | DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2019097434A1 (en) | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| WO2020102810A1 (en) | 2018-11-16 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
-
2018
- 2018-11-05 US US16/180,984 patent/US20190135741A1/en not_active Abandoned
- 2018-11-06 JP JP2019535295A patent/JP2021502323A/ja active Pending
- 2018-11-06 KR KR1020227002489A patent/KR20220016304A/ko not_active Ceased
- 2018-11-06 RU RU2019126848A patent/RU2019126848A/ru unknown
- 2018-11-06 CA CA3131442A patent/CA3131442A1/en active Pending
- 2018-11-06 CN CN201880047207.0A patent/CN111201017A/zh active Pending
- 2018-11-06 KR KR1020207016592A patent/KR102357471B1/ko active Active
- 2018-11-06 WO PCT/US2018/059446 patent/WO2019094383A1/en not_active Ceased
- 2018-11-06 EP EP18876329.6A patent/EP3534890A4/en not_active Withdrawn
- 2018-11-06 CA CA3046363A patent/CA3046363C/en active Active
- 2018-11-06 AU AU2018365900A patent/AU2018365900B2/en active Active
-
2020
- 2020-07-14 US US16/928,927 patent/US11753370B2/en active Active
- 2020-09-01 AU AU2020227015A patent/AU2020227015B2/en active Active
-
2022
- 2022-11-25 AU AU2022275499A patent/AU2022275499B9/en active Active
-
2025
- 2025-01-02 AU AU2025200018A patent/AU2025200018A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502323A5 (https=) | ||
| RU2019126848A (ru) | Способы производства дейтерий-обогащённого N-ацетилцистеин амида (D-NACA) и (2R,2R')-3,3'-дисульфанедиил бис(2-ацетамидопропанамида) (DINACA) и применение D-NACA и DINACA для лечения заболеваний, включающих окислительный стресс | |
| JP2018035160A5 (https=) | ||
| ES2396595T3 (es) | Composición farmacéutica que contiene un derivado de pirazina y método de utilización de un derivado de pirazina en combinación | |
| JP2010524975A5 (https=) | ||
| PH12021552881A1 (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| JP2013139446A5 (https=) | ||
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| JP2014503525A5 (https=) | ||
| JP2008520589A5 (https=) | ||
| CA2506082A1 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary disease | |
| JP2012521994A5 (https=) | ||
| JP2013010792A5 (https=) | ||
| JP2014511374A5 (https=) | ||
| JP2020502047A5 (https=) | ||
| JP2014530818A5 (https=) | ||
| JP2012522759A5 (https=) | ||
| CA2541781A1 (en) | 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| CN103228618B (zh) | 新化合物及其医药用途 | |
| RU2014109441A (ru) | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами | |
| JP2015511232A5 (https=) | ||
| CN108623451B (zh) | 一种多臂单一分子量聚乙二醇及其活性衍生物及其制备和应用 | |
| JP2013516475A5 (https=) | ||
| JP2007518798A5 (https=) |